SynthesisAsian journal of andrology
The PCA3 test for guiding repeat biopsy of prostate cancer and its cut-off score: a systematic review and meta-analysis.
Synthesis in Asian journal of andrology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The research progress on diagnostic indicators related to prostate-specific antigen gray-zone prostate cancer.BMC cancer · 2025Pooled it
- Article
- Article
- Urinary PCA3 a Superior Diagnostic Biomarker for Prostate Cancer among Ghanaian Men.Disease markers · 2022Article
- Biomarkers in Prostate Cancer Diagnosis: From Current Knowledge to the Role of Metabolomics and Exosomes.International journal of molecular sciences · 2021Review
- Commercialized Blood-, Urinary- and Tissue-Based Biomarker Tests for Prostate Cancer Diagnosis and Prognosis.Cancers · 2020Review
- How should radiologists incorporate non-imaging prostate cancer biomarkers into daily practice?Abdominal radiology (New York) · 2020Review
- Biomarkers in the setting of benign prostatic hyperplasia-induced lower urinary tract symptoms: what an interventional radiologist needs to know.The British journal of radiology · 2020Review
- Diagnostic accuracy of prostate cancer antigen 3 (PCA3) prior to first prostate biopsy: A systematic review and meta-analysis.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2020Article
- Biomarkers for detecting prostate cancer: Protocol for an umbrella review with integrated network meta-analysis.Medicine · 2019Article
- Urinary markers aiding in the detection and risk stratification of prostate cancer.Translational andrology and urology · 2018Review
- Are localized prostate cancer biomarkers useful in the clinical practice?Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2018Review
- Longitudinal assessment of urinary PCA3 for predicting prostate cancer grade reclassification in favorable-risk men during active surveillance.Prostate cancer and prostatic diseases · 2017Article
- Somatic Mutation Analyses in Studies of the Clonal Evolution and Diagnostic Targets of Prostate Cancer.Current genomics · 2017Review
- Recent progress and perspectives on prostate cancer biomarkers.International journal of clinical oncology · 2017Review
- Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy.Cancers · 2017Review
- Novel Gene Expression Signature Predictive of Clinical Recurrence After Radical Prostatectomy in Early Stage Prostate Cancer Patients.The Prostate · 2016Article
- Biomarkers in localized prostate cancer.Future oncology (London, England) · 2016Review
- The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements.Biomarkers in cancer · 2016Review
- Screening for Prostate Cancer-Beyond Total PSA, Utilization of Novel Biomarkers.Current urology reports · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The specificity of prostate-specific antigen (PSA) for early intervention in repeat biopsy is unsatisfactory. Prostate cancer antigen 3 (PCA3) may be more accurate in outcome prediction than other methods for the early detection of prostate cancer (PCa). However, the results were inconsistent in repeated biopsies. Therefore, we performed a systematic review and meta-analysis to evaluate the role of PCA3 in outcome prediction. A systematic bibliographic search was conducted for articles published before April 2013, using PubMed, Medline, Web of Science, Embase and other databases from health technology assessment agencies. The quality of the studies was assessed on the basis of QUADAS criteria. Eleven studies of diagnostic tests with moderate to high quality were selected. A meta-analysis was carried out to synthesize the results. The results of the meta-analyses were heterogeneous among studies. We performed a subgroup analysis (with or without inclusion of high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical small acinar proliferation (ASAP)). Using a PCA3 cutoff of 20 or 35, in the two sub-groups, the global sensitivity values were 0.93 or 0.80 and 0.79 or 0.75, specificities were 0.65 or 0.44 and 0.78 or 0.70, positive likelihood ratios were 1.86 or 1.58 and 2.49 or 1.78, negative likelihood ratios were 0.81 or 0.43 and 0.91 or 0.82 and diagnostic odd ratios (ORs) were 5.73 or 3.45 and 7.13 or 4.11, respectively. The areas under the curve (AUCs) of the summary receiver operating characteristic curve were 0.85 or 0.72 and 0.81 or 0.69, respectively. PCA3 can be used for repeat biopsy of the prostate to improve accuracy of PCa detection. Unnecessary biopsies can be avoided by using a PCa cutoff score of 20.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.